Last reviewed · How we verify
ODM-104
At a glance
| Generic name | ODM-104 |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-finding Pharmacokinetic Study in Healthy Males (PHASE1)
- Blood-Brain Barrier Penetration of Therapeutic Agents in Human (PHASE1)
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) (PHASE2)
- Pharmacokinetic of Levodopa Study in Healthy Males (PHASE1)
- Pharmacokinetic Study in Healthy Volunteers (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers (PHASE1)
- Pharmacokinetic Study in Healthy Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ODM-104 CI brief — competitive landscape report
- ODM-104 updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI